Main Capital, a boutique investment firm, released its first-quarter 2025 investor letter. A copy of the letter can be ...

Discover why biotech stock ARVN, trading at a 70% discount to cash value, offers potential upside despite setbacks.

Arvinas Inc (ARVN) reports a significant revenue increase and outlines strategic moves to extend its cash runway and enhance its drug development pipeline.

Fintel reports that on May 5, 2025, Truist Securities downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Buy to Hold.

Arvinas (NASDAQ:ARVN) stock drops 33% after announcing workforce cuts and trial removals, despite beating earnings expectations. Read more here.

New Haven-based Arvinas will lay off 131 employees, with 92 in Connecticut, as part of a major workforce reduction.

Ratings for Arvinas ARVN were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings ...

Fintel reports that on May 2, 2025, Jefferies downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Buy to Hold. Analyst Price Forecast Suggests 238.05% Upside As of April 24, 2025, the average ...

Shares of Arvinas stock opened at $7.72 on Friday. The firm has a market capitalization of $563.49 million, a PE ratio of -2.79 and a beta of 2.21. The firm’s 50 day moving average is $9.66 and ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data. Arvinas disclosed the rethink alongside news that it is laying off ...

Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. The business’s quarterly revenue was up 646.2% compared to the same quarter last year.

Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuro ...